N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Phase 4 N=395 Nephropathy In Type 2 Diabetes and Cardio-renal Events
Diabetic Nephropathy
Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05
N/A N=507 Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
Type 2 Diabetes
Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24
N/A N=18 Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Insulin Sensitivity · Multiple Mitochondrial Dysfunctions Syndrome
Primary: Change in Insulin Sensitivity — 3.18; 3.85; 3.57; 5.22 mg/kg.min per µU/ml
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
Phase 3 N=127 Vitamin D for Established Type 2 Diabetes (DDM2)
Type 2 Diabetes
Primary: Disposition Index — 0.023; 0.149 index
Phase 3 N=796 Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
Diabetes Mellitus Type 2
Primary: Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo — -15.8; 2.1…
N/A N=601 Genetic Testing for Type 2 Diabetes
Diabetes Mellitus
Primary: Weight — 103.8; 100.7 kg — p=0.44
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
Phase 2 N=32 A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
Diabetes Mellitus, Type 2 · NASH - Nonalcoholic Steatohepatitis
Primary: Number of Treatment-Emergent Adverse Events — 0; 2 Adverse Events
N/A N=958 Gestational Diabetes Mellitus Trial (GDM)
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
N/A N=58 Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
N/A N=90 Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus
Gestational Diabetes Mellitus
Primary: The Concentration of Serum FGF19 — 65.96; 124.47 pg/mL
Phase 3 N=699 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Phase 3 N=9,306 Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Diabetes Mellitus, Type 2
Primary: Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan — 33.1; 36.8 Percentage of patients
N/A N=235 Type 2 Diabetes Exemplar: A Remote Care Service for North West London
Type 2 Diabetes Mellitus
Primary: % Participants Downloading Huma App — 95; 0 Participants
N/A N=1,523 A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
Type 2 Diabetes Mellitus
Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin
Phase 2 N=50 Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
Type 2 Diabetes
Primary: Insulin Secretion — 5; 29 % increase of Ins30
Phase 1 N=33 Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
Type 1 Diabetes Mellitus · Maturity-Onset Diabetes of the Young, Type 2 · MODY2
Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min
Phase 2 N=164 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Non-alcoholic Steatohepatitis
Primary: Percent Change From Baseline in Whole Liver Fat at Week 16 — -3.21; -16.12; -4.36 Percent change — p=0.0696
N/A N=102 Metformin in Overweight Type 2 Diabetes Mellitus
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
Phase 2 N=23 Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05
Phase 3 N=1,172 An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c at Week 52 — -0.67; -0.67 Percent
Phase 2 N=36 A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia
Diabetes Mellitus, Type 2 · Insomnia
Primary: Sleep Efficiency — 79.5; 83.1 Percentage of time asleep — p=0.04
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
Phase 2 N=188 Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Diabetes Type 2
Primary: Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements. — 13.70; -3.67; 6.64; 1.66 mg/dL — p=0.0117
Phase 3 N=91 An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
Diabetes Mellitus, Type 2 · Chronic Renal Insufficiency
Primary: Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment — 41; 16; 8; 1 Participants
Phase 4 N=108 Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
Diabetes Mellitus, Type 2
Primary: Number of Neonates With Composite Adverse Neonatal Outcome — 31; 35 Participants
Phase 2 N=7 A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis (NASH)
Primary: Number of Participants With Treatment-related Adverse Events. — 3 Participants